Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rob Jones

- PMLiVE

Parkinson’s UK and Parkinson’s Foundation partner to accelerate drug development

Parkinson's disease is the fastest growing neurological condition worldwide, currently affecting 145,000 people in the UK

- PMLiVE

AI: powering healthcare, empowering patients Physician perceptions of AI and the future of pharma

In the face of the coronavirus, innovative technologies such as artificial intelligence (AI) and machine learning (ML) have proven vital for the protection and promotion of public health.According to a...

- PMLiVE

Moderna seeks FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The application is based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

- PMLiVE

Pfizer and BioNTech release COVID-19 vaccine trial results for children under five

The phase 2/3 trial results showed that the vaccine was 73.2% effective in protecting children aged six months to four years

- PMLiVE

Roche launches digital PCR system to identify ultra-rare and emerging disease mutations

The diagnostics platform will allow researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions

- PMLiVE

Merck granted fast track designation by FDA for end-stage renal disease therapy

MK-2060 is currently being investigated in a phase 2 study to evaluate the efficacy and safety of two different doses

- PMLiVE

100,000 doses of Janssen’s COVID-19 delivered to Ukraine under COVAX initiative

WHO in Ukraine has trained more than 100 medical workers across the country to conduct further training on the use of Ad26.COV2-S

- PMLiVE

ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS

With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...

Wilmington Healthcare

- PMLiVE

Cannes Lions shows health creative is becoming an art form

If you ever want an example of art imitating life, look no further than Cannes Lions 2022. Because just like life these past two years – in fact possibly because...

- PMLiVE

EMA accepts Otsuka and Astex’s marketing authorisation application for acute myeloid leukaemia treatment 

The application is supported by results from a phase 3 trial demonstrating an exposure equivalence to the current standard of care for AML

- PMLiVE

Pfizer and BioNTech seek FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The companies have rapidly increased production of the newly developed vaccine and are ready to deliver doses from September

EU flag

EMA accepts Mundipharma’s application for invasive candidiasis treatment rezafungin

Despite currently available treatments, the mortality rate for patients with invasive candidiasis remains high at up to 40%

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links